Biotechnology company Shattuck Labs Inc revealed on Monday the addition of Casi DeYoung as its chief business officer.
Most recently, DeYoung has served as the chief operating officer at ImmuneSensor Therapeutics, with responsibility for corporate strategy, start-up operations, intellectual property, oversight of its first IND filing and the initiation of a first-in-human Phase 1 clinical trial.
Previously, DeYoung was employed as chief business officer at Mirna Therapeutics as well as operations director for oncology at EMD Pharmaceuticals and Merck KGaA.
Earlier in her career, DeYoung has worked as vice president of business development at Reata Pharmaceuticals as well as ODC Therapy
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval